Comparative Effectiveness of Anti-Tumor Necrosis Factor Drugs on Health-Related Quality of Life Among Patients With Inflammatory Arthritis-Reference-Cited by-同舟云学术

Comparative Effectiveness of Anti-Tumor Necrosis Factor Drugs on Health-Related Quality of Life Among Patients With Inflammatory Arthritis

Published:2014-02-24 Issue:3 Volume:66 Page:464-472
ISSN:2151-464X
Container-title:Arthritis Care & Research
language:en
Short-container-title:Arthritis Care & Research

Author:

Chen Jian Sheng¹,Makovey Joanna¹,Lassere Marissa²,Buchbinder Rachelle³,March Lyn M.¹

Affiliation:

1. Institute of Bone and Joint Research, Kolling Institute of Medical Research, University of Sydney; Sydney Australia

2. St George Hospital, University of New South Wales; Sydney Australia

3. Cabrini Institute and Monash University; Melbourne Australia

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/acr.22151/fullpdf

Reference32 articles.

2. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry;Greenberg;Ann Rheum Dis,2012

3. Biologics for rheumatoid arthritis: an overview of Cochrane reviews;Singh;Cochrane Database Syst Rev,2009

4. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity;Strand;Drugs,2010

5. The SF-36 health survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability;Kosinski;Med Care,1999

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review;Seminars in Arthritis and Rheumatism;2023-10

2. Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care;PLOS ONE;2022-05-05

3. A Versatile, Secure, and Sustainable All-in-One Biobank-Registry Data Solution: The A3BC REDCap Model;Biopreservation and Biobanking;2021-11-22

4. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry;Clinical Rheumatology;2019-07-29

5. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis;PLOS ONE;2019-07-24